Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 30.2% during mid-day trading on Thursday . The stock traded as high as C$0.29 and last traded at C$0.28. 1,182,171 shares were traded during mid-day trading, an increase of 75% from the average session volume of 676,254 shares. The stock had previously closed at C$0.22.
Hemostemix Trading Up 12.7 %
The firm has a market capitalization of C$27.01 million, a P/E ratio of -15.50 and a beta of 0.20. The business has a 50 day moving average of C$0.11 and a 200-day moving average of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- The How and Why of Investing in Gold Stocks
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- What Are the FAANG Stocks and Are They Good Investments?
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- Stock Sentiment Analysis: How it Works
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
